What's Hot
View all perspectives
Richard Conway RichardPAConway
3 years 1 month ago
GLORIA study of adding prednisolone 5mg to DMARDs over 2 years for RA in those >65 years. Mean DAS 0.37 points lower, Sharp score 1.7 lower (are either of these clinically significant?). NNH 9.5. To me causing harm chasing statistical benefit Abstr#1678 #ACR21 @RheumNow #ACRBest https://t.co/KYk1II3J3w
Richard Conway RichardPAConway
3 years 1 month ago
Avacopan effects on renal disease in AAV presented in further detail. Greater recovery with avacopan, which was accentuated in those with worse renal disease or proteinuria at baseline. Abstr#L14 #ACR21 @RheumNow https://t.co/dfTmhhsNnX
Dr. Rachel Tate uptoTate
3 years 1 month ago
Clinical and research pearl: SPACC vs LEEDs enthesitis scoring for your PsA patients by Dr. Ogdie. #ACR21 @RheumNow #RheumNow https://t.co/dDznwSicRQ
David Liew drdavidliew
3 years 1 month ago
I don't know much about antifibrotics in RA-ILD, but these data emphasise that HRCT pattern matters
My simple mind, for any disease:
multiple subtypes with different trajectories➡️likely to be differing responses to Rx
TRAIL1: pirfenidone in RA-ILD
#ACR21 ABSTL10 @RheumNow https://t.co/v7HCO0ZBe1
Mrinalini Dey DrMiniDey
3 years 1 month ago
#SARSCoV2 infections in vaccinated pts w/ #rheumaticdisease @rheum_covid @rheum_cat
👉🏼Most pts with breakthrough infections were on anti-metabolites or B-cell depleting therapies
👉🏼Encourage patients to get their #BoosterShot!
Abs#L04 #ACR21 @RheumNow
https://t.co/TAB4zrjPN1 https://t.co/z0gpsxN3xc
sheila RHEUMarampa
3 years 1 month ago
⬆HCQ blood levels significantly associated w/ ⬇ in mean SLEDAI, UPCR, SBP & platelet cts
🔷Assoc'n strongest in HCQ conc'n in range 0-1000ng/mL
A possible HCQ blood level target to ⬇ 👁toxicity?🤔
@RheumNow #ACR21 abs1753 https://t.co/3jkDDakIcb
Richard Conway RichardPAConway
3 years 1 month ago
Comparative effects of abatacept in RA-ILD with UIP/NSIP. Appears equally effective in stabilising FVC, DLCO, and HRCT findings in both. Abstr#1683 #ACR21 @RheumNow https://t.co/l0Ia1D9c56
Olga Petryna DrPetryna
3 years 1 month ago
Abst1510 #ACR21 @RheumNow in animal study Stimulation w/ SIINFEKL peptide induces proliferation of resident memory CD8+ T cells in target joint resulting in increased numbers of B cells, Neutrophils, and CD4 cells within the joint space =localized inflammatory arthritis https://t.co/QlYT8OyGTt
sheila RHEUMarampa
3 years 1 month ago
Interesting study on Pioglitazone significantly improving vascular stiffness and cardiometabolic parameters vs. PBO in #lupus by @sarfarazhasni et al.
Pioglitazone: potential tx option to reduce CV risk in SLE?🧐
@RheumNow #ACR21 abs1748 https://t.co/ow3zA2hhnx
Robert B Chao, MD doctorRBC
3 years 1 month ago
ePROs for SpA patients showed a trend in reduction of disease activity, improved clinic workload, individualized treatment with good patient/physician user satisfaction
Abs#1788
#ACR21 @RheumNow
https://t.co/04kUikdIZu https://t.co/uO9junUqKi
Richard Conway RichardPAConway
3 years 1 month ago
Sleep disturbance common and associated with disease activity (both PRO and physician-assessed) in RA. Need further studies to evaluate causal directions, but may well be bidirectional? Abstr#1666 #ACR21 @RheumNow https://t.co/eK65I92wPg
Eric Dein ericdeinmd
3 years 1 month ago
#ACR21 Ab#1683: ABA for RA-ILD
⭐️Stabilization of DLCO, FVC, HRCT in UIP and NSIP in 106 UIP, 84 NSIP patients
⭐️Stabilization or improvement of dyspnea in 91% UIP, 95% NSIP pts
@Rheumnow https://t.co/qfgDmooGOj https://t.co/gz6Jk15nUs
Eric Dein ericdeinmd
3 years 1 month ago
#ACR21 Ab#1699: ITIS diet:
⭐️Fatigue ⬇️ in 20 pts on ITIS trial, didn't correlate with final DAS28CRP
⭐️Fatigue responders (50% improvement) had different fecal microbiome changes & anti-inflamm compounds, than non-responders
@Rheumnow https://t.co/UvE2ZpxCDU
David Liew drdavidliew
3 years 1 month ago
For patients with inflammatory irAEs, what's your preference of bDMARD/tsDMARD?
(keeping in mind both irAE response and tumor response)
#ACR21 irAE Study Group run by @CCalabreseDO @NAbdelwahabMD @ReidMDMPH
@RheumNow
Aurelie Najm AurelieRheumo
3 years 1 month ago
☄️Late breakingTRAIL1 RCT Pirfenidone on RA-ILD.
✨Primary outcome on incidence of decline of >10% FVC or death not met 11% PIR vs. 15% PBO OR=0.67 p=0.48
BUT
✨underpowered
✨reduces decline in FVC(ml) over 52wk (-66 vs. -146, p=0.0082)
✨safety ok
#ACR21 #AbstL10
@RheumNow https://t.co/IxYDE3lN1s
Poster Hall